CZ296689B6 - Zpusob krystalizace 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinhydrochloridu, smes formy I a formy III 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinchloridu a farmaceutický prostredek obsahu - Google Patents

Zpusob krystalizace 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinhydrochloridu, smes formy I a formy III 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinchloridu a farmaceutický prostredek obsahu Download PDF

Info

Publication number
CZ296689B6
CZ296689B6 CZ0229299A CZ229299A CZ296689B6 CZ 296689 B6 CZ296689 B6 CZ 296689B6 CZ 0229299 A CZ0229299 A CZ 0229299A CZ 229299 A CZ229299 A CZ 229299A CZ 296689 B6 CZ296689 B6 CZ 296689B6
Authority
CZ
Czechia
Prior art keywords
ethyl
trifluoromethylphenyl
mixture
naphth
tetrahydropyridine hydrochloride
Prior art date
Application number
CZ0229299A
Other languages
Czech (cs)
English (en)
Other versions
CZ229299A3 (cs
Inventor
Caron@Antoine
Franc@Bruno
Monnier@Olivier
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CZ229299A3 publication Critical patent/CZ229299A3/cs
Publication of CZ296689B6 publication Critical patent/CZ296689B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CZ0229299A 1996-12-23 1997-12-23 Zpusob krystalizace 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinhydrochloridu, smes formy I a formy III 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinchloridu a farmaceutický prostredek obsahu CZ296689B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
CZ229299A3 CZ229299A3 (cs) 1999-09-15
CZ296689B6 true CZ296689B6 (cs) 2006-05-17

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0229299A CZ296689B6 (cs) 1996-12-23 1997-12-23 Zpusob krystalizace 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinhydrochloridu, smes formy I a formy III 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinchloridu a farmaceutický prostredek obsahu

Country Status (38)

Country Link
EP (1) EP0950050B1 (cg-RX-API-DMAC7.html)
JP (2) JP4499188B2 (cg-RX-API-DMAC7.html)
KR (1) KR100586670B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129580C (cg-RX-API-DMAC7.html)
AR (1) AR009672A1 (cg-RX-API-DMAC7.html)
AT (1) ATE307802T1 (cg-RX-API-DMAC7.html)
AU (1) AU736697B2 (cg-RX-API-DMAC7.html)
BR (1) BR9714081A (cg-RX-API-DMAC7.html)
CA (1) CA2275596C (cg-RX-API-DMAC7.html)
CO (1) CO5070688A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296689B6 (cg-RX-API-DMAC7.html)
DE (1) DE69734460T2 (cg-RX-API-DMAC7.html)
DK (1) DK0950050T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2383A1 (cg-RX-API-DMAC7.html)
EE (1) EE04188B1 (cg-RX-API-DMAC7.html)
EG (1) EG21567A (cg-RX-API-DMAC7.html)
ES (1) ES2251038T3 (cg-RX-API-DMAC7.html)
FR (1) FR2757543B1 (cg-RX-API-DMAC7.html)
HR (1) HRP970699B1 (cg-RX-API-DMAC7.html)
HU (1) HU227425B1 (cg-RX-API-DMAC7.html)
IL (1) IL129938A (cg-RX-API-DMAC7.html)
IN (1) IN186976B (cg-RX-API-DMAC7.html)
IS (1) IS2357B (cg-RX-API-DMAC7.html)
MY (1) MY118015A (cg-RX-API-DMAC7.html)
NO (1) NO312364B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336130A (cg-RX-API-DMAC7.html)
PL (1) PL190494B1 (cg-RX-API-DMAC7.html)
RS (1) RS49882B (cg-RX-API-DMAC7.html)
RU (1) RU2192416C2 (cg-RX-API-DMAC7.html)
SA (1) SA98180971B1 (cg-RX-API-DMAC7.html)
SI (1) SI0950050T1 (cg-RX-API-DMAC7.html)
SK (1) SK285088B6 (cg-RX-API-DMAC7.html)
TR (1) TR199901363T2 (cg-RX-API-DMAC7.html)
TW (1) TW518322B (cg-RX-API-DMAC7.html)
UA (1) UA60324C2 (cg-RX-API-DMAC7.html)
UY (1) UY24825A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998028271A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9711576B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111855A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
JP5870183B2 (ja) * 2011-04-15 2016-02-24 エムキュア ファーマシューティカルズ リミテッド リルピビリン中間体の合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
PL334256A1 (en) 2000-02-14
HUP0001387A2 (hu) 2000-09-28
CA2275596C (en) 2005-10-11
EG21567A (en) 2001-12-31
KR100586670B1 (ko) 2006-06-07
TW518322B (en) 2003-01-21
PL190494B1 (pl) 2005-12-30
DE69734460D1 (de) 2005-12-01
EP0950050A1 (fr) 1999-10-20
NO993076D0 (no) 1999-06-22
AU5668498A (en) 1998-07-17
JP4499188B2 (ja) 2010-07-07
IL129938A (en) 2004-06-20
FR2757543B1 (fr) 1999-04-02
CN1129580C (zh) 2003-12-03
FR2757543A1 (fr) 1998-06-26
AR009672A1 (es) 2000-04-26
EE9900264A (et) 2000-02-15
UY24825A1 (es) 1998-04-21
SA98180971B1 (ar) 2006-09-13
HU227425B1 (en) 2011-05-30
CA2275596A1 (en) 1998-07-02
RS49882B (sr) 2008-08-07
MY118015A (en) 2004-08-30
CZ229299A3 (cs) 1999-09-15
JP2009197022A (ja) 2009-09-03
IN186976B (cg-RX-API-DMAC7.html) 2001-12-22
ES2251038T3 (es) 2006-04-16
CO5070688A1 (es) 2001-08-28
UA60324C2 (uk) 2003-10-15
DK0950050T3 (da) 2006-01-23
ZA9711576B (en) 1998-06-25
EP0950050B1 (fr) 2005-10-26
HK1024002A1 (en) 2000-09-29
HRP970699A2 (en) 1998-10-31
SK82899A3 (en) 1999-12-10
EE04188B1 (et) 2003-12-15
TR199901363T2 (xx) 1999-08-23
RU2192416C2 (ru) 2002-11-10
YU28999A (sh) 2003-01-31
SI0950050T1 (sl) 2006-04-30
NO993076L (no) 1999-06-22
DE69734460T2 (de) 2006-07-06
WO1998028271A1 (fr) 1998-07-02
CN1241180A (zh) 2000-01-12
HRP970699B1 (en) 2007-03-31
KR20000069504A (ko) 2000-11-25
NO312364B1 (no) 2002-04-29
ATE307802T1 (de) 2005-11-15
IL129938A0 (en) 2000-02-29
IS5076A (is) 1999-06-10
JP2001507012A (ja) 2001-05-29
AU736697B2 (en) 2001-08-02
SK285088B6 (sk) 2006-06-01
NZ336130A (en) 2001-01-26
IS2357B (is) 2008-04-15
DZ2383A1 (fr) 2002-12-28
HUP0001387A3 (en) 2002-03-28
BR9714081A (pt) 2000-05-09

Similar Documents

Publication Publication Date Title
CA2350956C (en) New crystals of celecoxib
JPS63215664A (ja) Ｏ‐置換テトラヒドロピリジンオキシムコリン作動剤
EP1505066A1 (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
CZ296689B6 (cs) Zpusob krystalizace 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinhydrochloridu, smes formy I a formy III 1-[2-(naft-2-yl)ethyl]-4-(3-trifluormethylfenyl)-1,2,3,6-tetrahydropyridinchloridu a farmaceutický prostredek obsahu
SK135195A3 (en) Crystaline spirostalnylglycosidal, its monohydrate pharmaceutical agent on its base and method of production of crystaline steroid glycoside
HUT59391A (en) Process for producing 1-(3,4-dihydro-2-oxo-1h-quinoline-6-yl)-2-/4-(2-phenylethyl)-piperidin-1-yl/ethanol and -ethanone, as well as pharmaceutical compositions comprising such compounds as active ingredient
US6489334B2 (en) Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
MXPA99005620A (en) Method for the crystallisation of a tetrahydopyridin derivative and resulting crystalline forms
RU2193031C2 (ru) Форма гидрохлорида 1-[2-(2-нафтил)этил]-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина в виде микрочастиц, фармацевтическая композиция на ее основе
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
US20030191141A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
WO2003042161A1 (en) Venlafaxine hydrochloride polymorphs
HRP970701A2 (en) Micro-particulate form of a tetrahydropyridin derivative
CZ20003722A3 (cs) Maleat paroxetinu
EP1149080A2 (en) Crystalline form of benzoquinoline-3-one derivative as inhibitor of 5-alpha reductase
MXPA00009884A (en) Paroxetine maleate

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20111223